Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs

Journal of Clinical Pharmacology

Volumn 48, Issue 11, 2008, Pages 1350-1355

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benzodiazepines; Cytochrome P4503A; Gender effects

Indexed keywords

ADINAZOLAM; ALFENTANIL; ALPRAZOLAM; BROMAZEPAM; BUSPIRONE; CLOBAZAM; CYTOCHROME P450 3A; GLYCOPROTEIN P; MIDAZOLAM; NEFAZODONE; NIFEDIPINE; NIMODIPINE; TRAZODONE; TRIAZOLAM; ZOLPIDEM;

ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; GENDER; HUMAN; MALE; PHENOTYPE; SEX DIFFERENCE;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SEX FACTORS;

EID: 54049096401     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008323754     Document Type: Article

References (42)

1. Kaiser J. Gender in the pharmacy: does it matter ? Science. 2005 ; 308: 1572.
2. Kim JS, Nafziger AN Is it sex or is it gender ? Clin Pharmacol Ther. 2000 ; 68: 1-3.
3. Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999 ; 39: 1-7.
4. Dorne JL, Walton K., Renwick AG Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol. 2003 ; 41: 201-224.
5. Wilkinson GR Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996 ; 24: 475-490.
6. Burk O., Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 105-124.
7. Greenblatt DJ, He P., von Moltke LL, Court MH The CYP3 family. In: Ioannides C, ed. Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. Cambridge, UK: Royal Society of Chemistry; 2008: 354-383.
8. Dawkins K., Potter WZ Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull. 1991 ; 27: 417-426.
9. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992 ; 149: 587-595.
10. Harris RZ, Benet LZ, Schwartz JB Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995 ; 50: 222-239.
11. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996 ; 21: 123-128.
12. Pollock BG Gender differences in psychotropic drug metabolism. Psychopharmacol Bull. 1997 ; 33: 235-241.
13. Mugford CA, Kedderis GL Sex-dependent metabolism of xenobiotics. Drug Metab Rev. 1998 ; 30: 441-498.
14. Beierle I., Meibohm B., Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999 ; 37: 529-547.
15. Ciccone GK, Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. Br J Anaesth. 1999 ; 82: 255-265.
16. Cummins CL, Wu CY, Benet LZ Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002 ; 72: 474-489.
17. Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics ? Clin Pharmacokinet. 2002 ; 41: 329-342.
18. Pleym H., Spigset O., Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand. 2003 ; 47: 241-259.
19. Schwartz JB The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003 ; 42: 107-121.
20. Gandhi M., Aweeka F., Greenblatt RM, Blaschke TF Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004 ; 44: 499-523.
21. Cotreau MM, von Moltke LL, Greenblatt DJ The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005 ; 44: 33-60.
22. Chen ML Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther. 2005 ; 78: 322-329.
23. Anderson GD Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005 ; 14: 19-29.
24. Schwartz JB The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007 ; 82: 87-96.
25. Scandlyn M., Stuart E., Rosengren R. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008 ; 4: 413-424.
26. Bebia Z., Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004 ; 76: 618-627.
27. Zhu B., Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol. 2003 ; 55: 264-269.
28. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithormycin. Clin Pharmacol Ther. 1998 ; 64: 133-143.
29. Gorski JC, Vannaprasaht S., Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003 ; 74: 275-287.
30. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999 ; 66: 461-471.
31. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J Clin Psychopharmacol. 1995 ; 15: 259-262.
32. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI Pharmacokinetics, pharmacodynamics, and drug disposition. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Williams; 2002: 507-524.
33. Wolbold R., Klein K., Burk O., et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003 ; 38: 978-988.
34. Hunt CM, Westerkam WR, Stave GM Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992 ; 44: 275-283.
35. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther. 1990 ; 48: 365-374.
36. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich FP Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994 ; 270: 414-423.
37. George J., Byth K., Farrel GC Age but not gender selectivity affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 1995 ; 50: 727-730.
38. Transon C., Lecoeur S., Leeman T., Beaune P., Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol. 1996 ; 51: 79-85.
39. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 ; 62: 248-260.
40. Parkinson A., Mudra DR, Johnson C., Dwyer A., Carroll KM The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004 ; 199: 193-209.
41. He P., Court MH, Greenblatt DJ, von Moltke LL Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos. 2006 ; 34: 1198-1207.
42. Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression ? Drug Metab Dispos. 2005 ; 33: 426-433.